



HAL
open science

Biological exploration of a novel 1,2,4-triazole-indole hybrid molecule as antifungal agent

Fabrice Pagniez, Nicolas Lebouvier, Young Min Na, Isabelle Ourliac-Garnier, Carine Picot, Marc Le Borgne, Patrice Le Pape

► To cite this version:

Fabrice Pagniez, Nicolas Lebouvier, Young Min Na, Isabelle Ourliac-Garnier, Carine Picot, et al.. Biological exploration of a novel 1,2,4-triazole-indole hybrid molecule as antifungal agent. *Journal of Enzyme Inhibition and Medicinal Chemistry*, 2020, 35 (1), pp.398-403. 10.1080/14756366.2019.1705292 . hal-02455791v1

HAL Id: hal-02455791

<https://hal.science/hal-02455791v1>

Submitted on 29 Aug 2024 (v1), last revised 24 Sep 2024 (v2)

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Volume 35 Issue 1 2020

Biological exploration of a novel 1,2,4-triazole-indole hybrid molecule as antifungal agent

Fabrice Pagniez, Nicolas Lebouvier, Young Min Na, Isabelle Ourliac-Garnier, Carine Picot, Marc Le Borgne & Patrice Le Pape

To cite this article: Fabrice Pagniez, Nicolas Lebouvier, Young Min Na, Isabelle Ourliac-Garnier, Carine Picot, Marc Le Borgne & Patrice Le Pape (2020) Biological exploration of a novel 1,2,4-triazole-indole hybrid molecule as antifungal agent, Journal of Enzyme Inhibition and Medicinal Chemistry, 35:1, 398-403, DOI: [10.1080/14756366.2019.1705292](https://doi.org/10.1080/14756366.2019.1705292)

To link to this article: <https://doi.org/10.1080/14756366.2019.1705292>



© 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.



Published online: 03 Jan 2020.



Submit your article to this journal [↗](#)



Article views: 2167



View related articles [↗](#)



View Crossmark data [↗](#)








Citing articles: 29 View citing articles [↗](#)

RESEARCH PAPER



Biological exploration of a novel 1,2,4-triazole-indole hybrid molecule as antifungal agent

Fabrice Pagniez^a , Nicolas Lebouvier^{b,c} , Young Min Na^b, Isabelle Ourliac-Garnier^a , Carine Picot^a, Marc Le Borgne^{b,d}  and Patrice Le Pape^a 

^aDépartement de Parasitologie et Mycologie Médicale, Université de Nantes, Nantes Atlantique Universités, EA1155 - ICI-Med, Institut de Recherche en Santé 2, Nantes, France; ^bDépartement de Chimie Thérapeutique, Université de Nantes, Nantes Atlantique Universités, EA1155 - ICI-Med, Institut de Recherche en Santé 2, Nantes, France; ^cInstitut des Sciences Exactes et Appliquées (ISEA) - EA 7484, Université de la Nouvelle-Calédonie, Noumea Cedex, New Caledonia; ^dEA 4446 Bioactive Molecules and Medicinal Chemistry, Faculté de Pharmacie - ISPB, SFR Santé Lyon-Est CNRS UMS3453 - INSERM US7, Université de Lyon, Université Claude Bernard Lyon 1, Lyon, France

ABSTRACT

(2-(2,4-Dichlorophenyl)-3-(1*H*-indol-1-yl)-1-(1,2,4-1*H*-triazol-1-yl)propan-2-ol (**8g**), a new 1,2,4-triazole-indole hybrid molecule, showed a broad-spectrum activity against *Candida*, particularly against low fluconazole-susceptible species. Its activity was higher than fluconazole and similar to voriconazole on *C. glabrata* (MIC₉₀ = 0.25, 64 and 1 µg/mL, respectively), *C. krusei* (MIC₉₀ = 0.125, 64 and 0.125 µg/mL, respectively) and *C. albicans* (MIC₉₀ = 0.5, 8 and 0.25 µg/mL, respectively). The action mechanisms of **8g** were also identified as inhibition of ergosterol biosynthesis and phospholipase A2-like activity. At concentration as low as 4 ng/mL, **8g** inhibited ergosterol production by 82% and induced production of 14α-methyl sterols, that is comparable to the results obtained with fluconazole at higher concentration. **8g** demonstrated moderate inhibitory effect on phospholipase A2-like activity being a putative virulence factor. Due to a low MRC5 cytotoxicity, this compound presents a high therapeutic index. These results pointed out that **8g** is a new lead antifungal candidate with potent ergosterol biosynthesis inhibition.

ARTICLE HISTORY

Received 20 October 2019
Revised 1 December 2019
Accepted 5 December 2019

KEYWORDS

Triazole-indole hybrid;
Candida species; ergosterol
production; phospholipase
A2-like activity;
in vivo evaluation

Introduction





During the last decades, the frequency of fungal infections has increased because of human immunodeficiency virus infection and more intensive and cytotoxic chemotherapies¹. In AIDS, oncology and transplantation patients, *Candida* still one of the major opportunistic pathogens^{2,3}. Options for treatment of severe fungal infections are primarily amphotericin B, azole compounds and echinocandins⁴. Although amphotericin B and its lipid formulations decrease the morbidity and mortality, they must be given intravenously, are extremely expensive and still carry significant infusion-related toxicity. Echinocandins, one of the first-line therapy in neutropenic patients reveal a high antifungal activity against *Candida spp.*⁵. However, resistance emergence has been described for *C. albicans* and the haploid yeast *C. glabrata*⁶. Furthermore, elevated MICs have been reported in the case of *C. parapsilosis*.

Fluconazole and fourth generation of azoles (e.g. voriconazole, posaconazole and isavuconazole) remain the most frequently used drugs for treatment of *Candida* infections⁷. However, azole resistance of *C. albicans* and non-*albicans Candida*, such as *C. krusei* and *C. glabrata*, naturally resistant or low-sensitive to fluconazole, have been reported^{8,9}. Even if new targets have been successfully explored as well as cell wall formation¹⁰, ergosterol synthesis inhibition has been the major objective of new antifungal drugs being ravuconazole and isavuconazole the most recent clinically

available drugs. Most of new antifungal targets presented in the literature exhibited little potential to develop target-based inhibitors being pharmacomodulation of non-toxic azole a good alternative¹¹.

Indolylazole derivatives are a new class of azole antifungal drugs¹² which have demonstrated *in vitro* activities against *Aspergillus*¹³ and protozoa such as *Leishmania*^{14,15}. More recently, structural modifications were done to enable a specific and broad activity against *Candida spp.*, including fluconazole low-susceptible species as *C. krusei* and *C. glabrata*.

Candida spp. are known to produce several types of phospholipases such as phospholipase B and phospholipase A which were detected in culture supernatant^{16,17}. The virulence of *Candida* strains in *G. mellonella* is related to the quantity of phospholipases production¹⁸ and strains isolated from symptomatic women with vulvovaginal candidiasis exhibit high level of phospholipase activity¹⁹. Phospholipase B has been described as a pathogenic factor that contributes to host membrane degradation and penetration of *C. albicans pseudohyphae*²⁰. Intracellular phospholipases, identified as phospholipases A, have been localised at the site of bud formation²¹. Triglyceride lipases with phospholipase A2-like activity (patatin-like homologs) have been described in *Saccharomyces* and *Candida*²². Already known function of this phospholipase is hydrolysis of fatty acids for membrane formation and sporulation. Since indole derivatives have been reported as inhibitors of

CONTACT Patrice Le Pape  patrice.le-pape@univ-nantes.fr  Department of Parasitology and Medical Mycology, ICI-Med UPRES EA 1155, Institut de Recherche en Santé 2, Université de Nantes, 22 Boulevard Bénoni Goullin, 44200 Nantes, France; Marc Le Borgne  marc.le-borgne@univ-lyon1.fr  EA 4446 Bioactive Molecules and Medicinal Chemistry, Faculté de Pharmacie - ISPB, Université Claude Bernard Lyon 1, 8 avenue Rockefeller, Lyon cedex 8, F-69373, France

© 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

phospholipase A₂ activity^{10,23} our 2-(2,4-dichlorophenyl)-3-(1H-indol-1-yl)-1-(1H-indol-1-yl)-propan-2-ol derivative (**8 g**) could be of interest to inhibit this enzyme activity.

In this work, we present the potent anti-*Candida* activity of **8 g**, an indole-triazole derivative, against *C. albicans* and non-*albicans* clinical isolates and its mechanism of action as inhibitor of ergosterol biosynthesis and phospholipase A₂-like activity.

Materials and methods

Strains

Control strains used for *in vitro* evaluation were the CLSI reference strains, including *Candida albicans* ATCC 2091, *C. glabrata* CBS 138, *C. krusei* ATCC 6258, *C. parapsilosis* ATCC 22019 and *C. parapsilosis* ATCC 90018. Additionally, numerous clinical isolates from the collection of EA1155 IICiMed were used: *C. albicans* ($n = 26$), *C. glabrata* ($n = 12$), *C. krusei* ($n = 14$), *C. parapsilosis* ($n = 18$) and *C. tropicalis* ($n = 6$). The selected species are representative of the European epidemiology and therefore correspond to the five most prevalent species in the clinic settings²⁴. Strains were maintained and subcultured 24 h before used on Sabouraud's agar slants.

Chemicals

Indole-triazole derivative compound **8 g**, 2-(2,4-dichlorophenyl)-3-(1H-indol-1-yl)-1-(1,2,4-1H-triazol-1-yl)-propan-2-ol (Figure 1), was synthesised in the Department of Medicinal Chemistry, EA1155 IICiMed. The chemical synthesis route of **8 g** and its derivatives (not described in this article) was achieved with regard to the synthesis of new analogues of fluconazole.²⁵ **8 g** was dissolved in DMSO to prepare a stock solution at 10 mg/mL. This stock solution was diluted in RPMI 1640 for *in vitro* experiment. For *in vivo* studies, to avoid injecting DMSO, compound **8 g** was prepared in 0.5% Tween 20-sterile saline solution. Fluconazole and voriconazole (Pfizer) were obtained from Mycobiotics. Stock solutions were prepared in water and DMSO, respectively, at a concentration of 10 mg/mL.

Antifungal susceptibility testing

MICs for *Candida* strains were determined by the broth microdilution method with RPMI 1640 medium (Sigma Aldrich, Saint Quentin fallavier, France) according to the procedures of the Clinical and Laboratory Standard Institute described in document M27-A2²⁶. Yeasts were grown on Sabouraud dextrose agar (Difco Laboratories) at 35 °C for 24 h. The wells were inoculated with 100 µL of the culture suspension diluted to a final inoculum of 5×10^2 to 2.5×10^3 cells/mL. Fungal growth was observed 48 h after incubation at 35 °C. The MICs of the azoles were the lowest drug concentrations to give a 50% decrease in turbidity from that of




Figure 1. Chemical structure of **8 g**.

the control fungal growth. MIC₉₀ was the concentration of a drug required at which 90% of the clinical isolates tested were inhibited.

MRC5 toxicity assay

Cytotoxicity of compounds was studied with human fibroblast (MRC5). Cells were grown in RPMI 1640 medium (Sigma-aldrich) supplemented with 10% foetal bovin serum (Sigma-aldrich). Drugs were tested at three concentrations (100, 10 and 1 µM) in triplicate. After a 96 h-incubation time cytotoxicity was measured on the Fluorolite 1000 (Dynatech, France) after a 4-h incubation time with Uptiblu[®] (Interchim, Montluçon, France). Inhibitory concentration 50 is a mean of triplicate values. A toxicity index was determined as follow: IC₅₀ against MRC5/Geometric mean of the MICs against *Candida spp.*

Phospholipase A₂ activity

Phospholipase A₂-like activity (PLA₂) was quantified in cells and culture supernatant of *C. albicans* CA98001 clinical isolate incubated for 1 h at 37 °C with the specific modified phospholipase A₂ substrate, 1-octadecanoyl-2-(1-¹⁴C)-eicosatetraenoyl-glycerol-3-phosphocholine. Lipids were extracted with chloroform/methanol mixture. Aliquots of chloroformic phases were placed in scintillation flasks for measures of total lipid radioactivity. The chromatography solvent phase was toluene/dioxane/acetic acid/formic acid 85/15/0.2/0.2 (v/v). Lipid classes were visualised with iodine vapours on an analytical thin-layer chromatography. Each spot was cut and the lipids were solubilised in scintillation liquid. Then, radioactivity was measured in a LKB 1909 scintillation spectrophotometer⁸. PLA₂ activity was expressed as the ratio of radioactive fatty acids versus total radioactivity of sample.

Compound **8 g** was introduced 30 min before the radioactive substrate at a concentration of 10 µM. A known inhibitor of PLA₂, the 4-bromophenacyl bromide (BpB) was used as reference at a concentration of 10 µM.

Sterol extraction

To study sterol synthesis, *Candida albicans* CAAL93, *C. krusei* CAKR7 and *C. glabrata* CAGL2 blastopores were incubated in 50 ml Sabouraud broth medium (Sigma) during 18 h at 35 °C with stirring. Cells were collected by centrifugation at 1500 g. Pellet was suspended in 3 ml of fresh ethanolic potassium hydroxide solution (25 g of KOH, 36 ml of distilled water and brought to 100 ml with 100% ethanol). Saponification was performed at 80 °C for 60 min. Sterols were extracted by addition of 3 ml of hexane and the organic phase was then washed by adding 1 ml of sterile water. Final organic phase was transferred to a new collection tube after 5 min centrifugation step at 2000 rpm.

Sterol analysis

Sterols as TMS derivatives were analysed by GC-MS using an Agilent 6890 N GC system, with a HP-5MS column (30 m x 0.25 mm ID, 0.25 µm film thickness, Agilent Technologies) coupled with a quadrupole mass detector (Agilent 5973i – E.I. 70 eV). Two microliters of sample were injected in splitless mode at 250 °C. The carrier gas was helium at a flow rate of 1.2 mL/min. The oven was set at 150 °C for 0.5 min and then raised to 280 °C at 40 °C/min and from 280 °C to 300 °C at 2 °C/min. Sterols were identified

via their electron ionisation fragmentation pattern, compared to published data. Results are expressed as percent area of total sterols.

In vivo activity

Animal use and care

Swiss female mice (Janvier Labs, Le Genest-Saint-Isle, France) with a body weight of ~25 g were obtained and allowed to acclimate for a minimum of 5 days prior to use. Environmental controls for the animal room were set to maintain a temperature of 16 to 22 °C, a relative humidity of 30 to 70%, and a 12:12 hourly light-dark cycle.

Systemic *C. albicans* infection model

Mice (8 per groups) were immunodepressed by subcutaneous injection of 30 mg/kg prednisolone one day before challenge. On day 0, mice were infected intravenously with *C. albicans* (CAAL93) blastoconidia (5.10^5 in 100 μ L of NaCl 0.9%). One hour after infection, mice were treated intraperitoneally for five consecutive days with 100 μ L 0.5% Tween 20-sterile saline solution (control), twice daily with 30 mg/kg or three times a day with 20 mg/kg body weight of compound **8g**. Fluconazole (Sigma, St Quentin Fallavier, France) was administered *per os* three times a day at 5 mg/kg. Mice were monitored for 14 days post inoculation. For reduction of animal distress, the body weights of the mice were recorded daily, and when they lost 20% of their initial weight, mice were euthanized. On day 14, all surviving mice were euthanized.

Statistical analysis

The results were statistically analysed using the software Graphpad PRISM 7.0. The log-rank (Mantel-Cox) test was performed for survival analysis. A *p* values < 0.05 was considered significant.

Results

Antifungal activities (MICs) of **8g** and reference compounds (fluconazole and voriconazole) against our set of clinical *Candida* strains are summarised in Table 1. Against CLSI quality control strains, MICs of **8g** were 0.125, 0.016 and 0.032 μ g/mL for *C. krusei*

ATCC6258, *C. parapsilosis* ATCC22019 and *C. parapsilosis* ATCC90018, respectively. This compound displayed high significant *in vitro* activity against the most clinically important species tested especially against low-susceptible or resistant *C. glabrata* and *C. krusei*. Indeed, **8g** was always more potent than fluconazole and at least as potent as voriconazole. MIC_{90s} against *C. glabrata* and *C. krusei* were as low as 0.25 and 0.125 μ g/mL, respectively, while MIC_{90s} of fluconazole were 64 and > 64 μ g/mL, respectively. MIC_{90s} of voriconazole were 4 and 4 μ g/mL, respectively. MIC_{90s} against completely tested strains were 0.5, 64 and 1 μ g/mL for **8g**, fluconazole and voriconazole, respectively.

Cytotoxicity evaluated on human fibroblast (MRC5) showed an IC₅₀ of 35 μ M for **8g** that is lower than for fluconazole or voriconazole (IC₅₀ >100 μ M). Nevertheless, its cytotoxicity occurred at concentration 280-time higher than geometric mean MIC against *Candida* (while fluconazole and voriconazole toxicity index were > 15 and > 590, respectively).

Compound **8g** was evaluated *in vivo* in a mouse model of systemic candidiasis. Survival of mice was significantly (*p* < 0.01) higher in fluconazole and **8g** groups than in the control group (Figure 2). In the fluconazole group (3 x 5 mg/kg) and in the **8g** group (3 x 20 mg/kg), all mice survived. Moreover, a treatment three times a day (3 x 20 mg/kg) was significantly (*p* < 0.05) more effective than twice a day (2 x 30 mg/kg).

A PLA2-like activity was clearly characterised in *C. albicans* CA98001, including cytosolic PLA2 (cPLA2) and secreted PLA2 activities. Indeed, using intact *Candida* cells, 53% and 34% of PLA2 activity was inhibited by 10 μ M BpB and **8g**, respectively (Table 2). In the case of **8g**, the impact on the production of arachidonic acid is marked (0.12 for **8g** versus 0.22 for the control).

GC-MS analysis of sterol profile of three different clinical strains of *C. albicans* (CAAL93), *C. krusei* (CAKR7) and *C. glabrata* (CAGL2)




Figure 2. Survival curve of mice after treatment with fluconazole (3 x 5 mg/kg *per os*, ●) or **8g** (2 x 30 mg/kg *ip*, △; 3 x 20 mg/kg *ip*, ▲). Control group (●). ***p* < 0.01; ****p* < 0.001.

Table 2. Hydrolysis inhibition of the 1-octadecanoyl 2-(¹⁴C) eicosatetraenoyl glycerol-3-phosphocholine after treatment with bromophenacyl bromide (BpB) and **8g**.

	Inhibitors (Mean \pm SEM)		
	Control	BpB	8g
phospholipids	1.18 \pm 0.18	1.32 \pm 0.01	1.10 \pm 0.01
mono- & diglycerides	0.12 \pm 0.04	0.12 \pm 0.01	0.14 \pm 0.02
arachidonic acid	0.22 \pm 0.04	0.11 \pm 0.01	0.12 \pm 0.02
triglycerides & others	0.26 \pm 0.13	0.31 \pm 0.16	0.12 \pm 0.01
total lipids	1.79 \pm 0.05	1.86 \pm 0.15	1.48 \pm 0.04
PLA2 like activity (%)	12.5 \pm 2.6	5.9 \pm 0.79	8.2 \pm 1.06

Radioactivity of the lipid classes is expressed in nmol.L⁻¹.min⁻¹/10⁸ cells. Phospholipase activity is expressed as the percentage of fatty acid released from the total radiolabelled phospholipids.

Table 1. Antifungal susceptibilities of *Candida* spp. to **8g**.

Species (no. of isolates)	Antifungal agent	MIC (μ g/mL)		
		Range	Geometric mean	MIC ₉₀
<i>C. albicans</i> (27)	8g	< 0.016–4	0.038	0.5
	fluconazole	< 0.125 – > 64	0.696	8
	voriconazole	< 0.016 – > 8	0.042	0.25
<i>C. glabrata</i> (13)	8g	< 0.06–0.5	0.06	0.25
	fluconazole	0.016 – > 64	4	64
	voriconazole	0.016–4	0.25	1
<i>C. krusei</i> (15)	8g	0.016–1	0.109	0.125
	fluconazole	8 – > 64	23	64
	voriconazole	0.016–4	0.158	0.125
<i>C. parapsilosis</i> (20)	8g	< 0.016–0.125	0.029	0.0625
	fluconazole	< 0.125 – > 64	0.661	8
	voriconazole	< 0.016–0.25	0.017	0.125
<i>C. tropicalis</i> (6)	8g	< 0.016–1		
	fluconazole	< 0.125–64		
	voriconazole	< 0.016–0.5		
<i>Candida</i> spp. (81)	8g	< 0.016–4	0.048	0.5
	fluconazole	< 0.125 – > 64	2	64
	voriconazole	< 0.016 – > 8	0.059	1

Table 3. Sterol profile of *C. albicans* (CAAL93), *C. krusei* (CAKR7) and *C. glabrata* (CAGL2) untreated and treated with fluconazole (FLU: 4 µg/mL) or **8g** (4 ng/mL or 4 µg/mL). -: not detected.

	R.T.	CAAL93			CAKR7			CAGL2		
		control	8g 4 ng/mL	FLU 4 µg/mL	control	8g 4 µg/mL	FLU 4 µg/mL	control	8g 4 µg/mL	FLU 4 µg/mL
zymosterol	9.34	4.8	–	–	2.4	–	–	–	–	–
24-ethyl-cholesta-5,7,22-trienol	9.49	–	–	8.5	–	–	–	–	–	–
ergosterol	9.55	69.4	21.6	–	83.1	60.1	84.3	78.4	41.6	79.9
14 α -methyl-episterol	9.71	–	13.5	30.7	–	3.5	–	–	2.6	–
ergosta-7,22-dienol	9.73	5.5	–	–	–	–	–	–	–	–
fecosterol	9.80	–	–	–	1.9	–	1.8	–	–	–
14 α -methylfecosterol	9.97	–	10.0	10.8	–	4.9	–	–	3.5	–
ergostadien-3 β -ol (5,7 or 5,8)	10.05	–	–	–	1.1	–	1.1	3.7	2.2	7.6
episterol	10.26	3.4	–	–	–	–	–	1.9	–	3.5
14α-3,6-diol	10.41	–	–	–	–	–	–	–	23.4	–
lanosterol	10.55	5.2	35.4	34.2	0.7	24.2	1.8	3.6	–	1.9
obtusifoliol	10.60	–	–	–	–	–	–	–	23.8	–
4,4-dimethylcholesta-8,24-dienol	10.80	1.4	–	–	1.2	–	1.1	2.7	–	2.1
eburicol	11.20	–	19.0	15.7	–	3.9	–	–	0.7	–
other sterols		10.3	0.5	0	9.5	3.5	10.0	9.6	2.2	7.1

R.T.: retention time; Other sterols: sterols <1% or unidentified sterols. Bold: sterols of major interest (lanosterol = precursor, ergosterol = final product and 14 α -3,6-diol = toxic final product)

showed ergosterol as the major sterol accounting for 69% to 83% of total cellular sterols. Small quantities of ergosterol intermediates such as zymosterol, ergosta-7,22-dienol, fecosterol and episterol were also detected to a lesser extent (between 2% and 5%). Ergosterol precursor in *Candida*, i.e. lanosterol, was also found in a small quantity (0.7% to 5.2%). These sterol profiles were in accordance with classical metabolism of ergosterol²⁷. Treatment with **8g** (4 ng/mL) of *C. albicans* fluconazole-susceptible strain (CAAL93 – MIC = 0.125 µg/mL) resulted in a significant reduction of ergosterol content (70%), an accumulation of lanosterol and the emerging of 14 α -methyl sterols such as eburicol, 14 α -methylfecosterol and 14 α -methyl-episterol. Same modifications in sterol profile were observed when CAAL93 was treated with fluconazole at a 1000-fold higher dose (4 µg/mL) (Table 3).

Two fluconazole-resistant strains (CAKR7, MIC \geq 64 µg/mL and CAGL2 MIC \geq 64 µg/mL) were treated with 4 µg/mL fluconazole and no effect on sterol profile was observed. However, when CAKR7 and CAGL2 strains were treated with **8g** at the same dose, a significant diminution of ergosterol content was observed (25% to 47%) as well as an accumulation of lanosterol or obtusifoliol. As for CAAL93, a production of 14 α -methyl-sterols was observed: eburicol, 14 α -methylfecosterol and 14 α -methyl-episterol. Toxic 14 α -methyl-diol was even detected for CAGL2 (23%). Modifications in sterol profiles after treatment with **8g** confirmed the blockage of 14 α -demethylase (ERG11) by this compound.

Discussion

Development of new antifungal drugs implies a high level of activity against targeted fungi and acceptable toxicity against host cells. In this aim, we have developed a new family of azole derivatives, indolyl-triazoles²⁵, that could inhibit yeast growth at low concentrations (MIC_{90S} < 0.50 µg/mL). The compound **8g** has a broad-spectrum activity against most clinical relevant *Candida* species. Against all *Candida* spp., MIC range of **8g** (< 0.016 – 4 µg/mL) was narrower than for fluconazole or voriconazole with MIC ranges of < 0.125 – > 64 µg/mL and < 0.016 – > 8 µg/mL, respectively. Against fluconazole low-susceptible spp. (*C. glabrata* and *C. krusei*), **8g** was more active than fluconazole and voriconazole. Because of their increasing frequency in bloodstream infection and their ability to resist to antifungal drugs, these species are now the real target of new drugs^{6,28}. **8g** inhibited their

growth at very low concentrations (MIC_{90S} = 0.25 µg/mL) whereas fluconazole and voriconazole have higher MIC_{90S}, 64 and 1 µg/mL, respectively. Moreover *C. albicans*, being the most frequently isolated species during invasive candidiasis, is highly sensitive to **8g** (MIC₉₀ < 0.5 µg/mL). Second-generation triazole antifungals (voriconazole, posaconazole, isavuconazole) have a broad anti-infectious spectrum. When tested against *Aspergillus fumigatus*, **8g** showed a moderate activity, since the concentration that inhibited 80% of the growth was 23 µg/mL. Because triazole derivatives (itraconazole, fluconazole and posaconazole) could inhibit ergosterol-like synthesis in Trypanosomatids²⁹, **8g** was tested against *Leishmania*. Results (data not shown) showed that **8g** was effective *in vitro* (IC₅₀ = 8 ± 2 µg/mL) against *Leishmania mexicana* promastigote stage. Further investigations must be done to evaluate activity against the most relevant amastigote stage encountered in human host.

In vivo, compound **8g** confirmed its antifungal activity against *C. albicans*. In a systemic candidiasis model, it was as effective as fluconazole to allow mice survival. In addition, the modification of the initial administration protocol (the same dose three-times a day instead of twice a day) gave a complete protection. This second protocol also highlighted the importance to spread out the daily dose of **8g**, thus providing 24 h of protection against a systemic candidiasis.

Several events are involved in the membrane biosynthesis, especially the production of lipids as sterols and phospholipids. We demonstrated that **8g** inhibits *Candida* ergosterol synthesis as observed with other azole drugs. This inhibition led to membrane integrity perturbations through ergosterol depletion, precursor accumulation (lanosterol) and production of alternative 14 α -methyl sterols (14 α -methylfecosterol, 14 α -methyl-episterol and 14 α -methyl-3,6-diol). Identification of 14 α -methylated sterols evidenced a blockage of CYP51 as a way of action of **8g**. Interestingly, the effects of **8g** on sterol metabolism are observed in CAAL93 (fluconazole susceptible strain) at 4 ng/mL whereas the same results are observed after fluconazole treatment at a 1000-fold higher concentration (4 µg/mL). Moreover, the same effects are seen when fluconazole-resistant strains (CAKR7 and CAGL2) were treated by **8g** at 4 µg/mL whereas nothing happened after treatment with the same dose of fluconazole. These results show the potency of this new indole-triazole derivative compound.

Phospholipids are vital structural and functional entities of biomembranes. Phosphatidylcholine, the major phospholipid, is in part metabolised by phospholipases A (PLAs). These enzymes are known to be essential for the turnover of the membrane phospholipids. Pugh *et al* showed that PLAs were present at the site of bud formation suggesting that they are involved in growth and change in shape of the cell wall²¹. With a different approach, previously used by Le Pape *et al*, we described a sn-2 hydrolytic phospholipase (PLA₂) activity in *Candida albicans*³⁰. After 1-h contact time, this activity was inhibited by **8g** suggesting an interaction with somatic PLA₂-like lipase. Whereas BpB decreased 12% of the glycerophospholipid hydrolysis, **8g** did not inhibit the secreted phospholipase activity (data not shown). However, no gene coding for PLA₂ was identified in yeast but lipases with patatin-like domains which have a cPLA₂-like activity, have already been described in *Saccharomyces cerevisiae* and in *C. albicans*^{22,31}. Patatin-like phospholipases role is well established for membrane biogenesis and sporulation, but their implication in virulence or pathogenesis had still to be determined. Such enzymes could be future targets for new antifungals. Thus, high **8g** concentrations (10 μM) could inhibit cell phospholipid organisation and could complete the main mechanism of action, e.g. inhibition of sterol biosynthesis.

Because of moderate toxicity on MRC5 cells but very low MIC against *Candida*, our compound exhibited a good safety (toxicity index = 280) as observed for reference drugs (fluconazole and voriconazole).

In conclusion, **8g** showed high *in vitro* activity against *Candida*, including low fluconazole-susceptible species (*C. krusei* and *C. glabrata*) which remain one of the main challenges in candidiasis therapy. Its mechanism of action involved a strong blockage of CYP51 and in a minor importance inhibition of PLA₂-like activity. This promising compound has low toxicity on MRC5 cells and a significant *in vivo* activity. Further investigations must be done to evaluate antifungal activity of **8g** and its enantiomers in *in vivo* models of candidiasis and against other fungi.

Acknowledgements

A doctoral scholarship from the Research Association AGISMED to Mr Y.-M. Na and Mr N. Lebouvier are gratefully acknowledged. We are also grateful to Mr. and Mrs. Le Floch (Yanikem s.a.r.l.) for their continued support.

Disclosure statement

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this article.

Funding

This research was also financially supported by Yang Ji Chemical Company of South Korea.

ORCID

Fabrice Pagniez  <http://orcid.org/0000-0002-1759-5106>
 Nicolas Lebouvier  <http://orcid.org/0000-0003-2280-7545>
 Isabelle Ourliac-Garnier  <http://orcid.org/0000-0002-8159-0959>
 Marc Le Borgne  <http://orcid.org/0000-0003-1398-075X>
 Patrice Le Pape  <http://orcid.org/0000-0001-5059-6402>

References

- Brown GD, Denning DW, Levitz SM. Tackling human fungal infections. *Science* 2012;336:647.
- Pappas PG, NIAID Mycoses Study Group, Rex JH, Lee J, et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. *Clin Infect Dis* 2003;37:634–43.
- Park BJ, Wannemuehler KA, Marston BJ, et al. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. *Aids* 2009; 23:525–30.
- Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases society of America. *Clin Infect Dis* 2016;62:e1–50.
- Pfaller MA, Boyken L, Hollis RJ, et al. *In vitro* susceptibilities of *Candida spp.* to caspofungin: four years of global surveillance. *J Clin Microbiol* 2006;44:760–3.
- Alexander BD, Johnson MD, Pfeiffer CD, et al. Increasing echinocandin resistance in *Candida glabrata*: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. *Clin Infect Dis* 2013;56: 1724–32.
- de Oliveira Santos GC, Vasconcelos CC, Lopes AJO, et al. *Candida* infections and therapeutic strategies: mechanisms of action for traditional and alternative agents. *Front Microbiol* 2018;9:1351.
- Carrillo-Muñoz AJ, Giusiano G, Ezkurra PA, Quindós G. Antifungal agents: mode of action in yeast cells. *Rev Esp Quimioter* 2006;19:130–9.
- Whaley SG, Berkow EL, Rybak JM, et al. Azole antifungal resistance in *Candida albicans* and emerging non-*albicans Candida* species. *Front Microbiol* 2016;7:2173.
- Kale P, Johnson LB. Second-generation azole antifungal agents. *Drugs Today (Barc)* 2005;41:91–105.
- Pouliot M, Jeanmart S. Pan assay interference compounds (PAINS) and other promiscuous compounds in antifungal research. *J Med Chem* 2016; 59:497–503.
- Na YM, Le BM, Pagniez F, et al. Synthesis and antifungal activity of new 1-halogenobenzyl-3-imidazolylmethylindole derivatives. *Eur J Med Chem* 2003;38:75–87.
- Pagniez F, Le Borgne M, Marchand P, et al. *In vitro* activity of a new antifungal azolyl-substituted indole against *Aspergillus fumigatus*. *J Enzyme Inhib Med Chem* 2002;17: 425–9.
- Marchand P, Le Borgne M, Na YM, et al. Synthesis and anti-leishmanial activity of 3-(alpha-azolylbenzyl)indoles. *J. Enzyme Inhib Med Chem* 2002;17:353–8.
- Na YM, Lebouvier N, Le Borgne M, et al. Synthesis and anti-leishmanial activity of 3-imidazolylalkylindoles. Part I. *J Enzyme Inhib Med Chem* 2004;19:451–7.
- Price MF, Cawson RA. Phospholipase activity in *Candida albicans*. *Sabouraudia* 1977;15:179–85.
- Mago N, Khuller GK. Subcellular localization of enzymes of phospholipid metabolism in *Candida albicans*. *J Med Vet Mycol* 1990;28:355–62.
- Rossoni RD, Barbosa JO, Vilela SF, et al. Correlation of phospholipase and proteinase production of *Candida* with *in vivo* pathogenicity in *Galleria mellonella*. *Braz J Oral Sci* 2013;12:199–204.
- Fule SR, Das D, Fule RP. Detection of phospholipase activity of *Candida albicans* and non *albicans* isolated from women

- of reproductive age with vulvovaginal candidiasis in rural area. *Indian J Med Microbiol* 2015;33:92–5.
20. Ghannoum MA. Potential role of phospholipases in virulence and fungal pathogenesis. *Clin Microbiol Rev* 2000;13:122–43.
 21. Pugh D, Cawson RA. The cytochemical localization of phospholipase A and lysophospholipase in *Candida albicans*. *Sabouraudia* 1975;13:110–5.
 22. Köhler GA, Brenot A, Haas-Stapleton E, et al. Phospholipase A2 and phospholipase B activities in fungi. *Biochim Biophys Acta* 2006;1761:1391–9.
 23. Schevitz RW, Bach NJ, Carlson DG, et al. Structure-based design of the first potent and elective inhibitor of human non-pancreatic secretory phospholipase A2. *Nat Struct Biol* 1995;2:458–65.
 24. Binder U, Lass-Flörl C. Epidemiology of invasive fungal infections in the Mediterranean. *Mediterr J Hematol Infect Dis* 2011;3:e20110016.
 25. (a) Le Borgne M, Na YM, Pagniez F, et al. Antifungal and/or antiparasitic pharmaceutical composition and novel indole derivatives as active principle of such a composition. US 0067998. 2004;(b) Lebouvier N, Giraud F, Corbin T, et al. Efficient microwave-assisted synthesis of 1-(1*H*-indol-1-yl)-2-phenyl-3-(1*H*-1,2,4-triazol-1-yl)propan-2-ols as antifungal agents. *Tetrahedron Lett* 2006;47:6479–83;(c) Lebouvier N, Pagniez F, Duflos M, et al. Synthesis and antifungal activities of new fluconazole analogues with azaheterocycle moiety. *Bioorg Med Chem Lett* 2007;17:3686–9.
 26. Clinical and Laboratory Standards Institute/National Committee for Clinical Laboratory Standards Reference method for broth dilution susceptibility testing of yeasts: approved standard, 2nd ed. Document M27-A2. Clinical and Laboratory Standards Institute. 2002; Wayne P.
 27. Alvarez-Rueda N, Fleury A, Morio F, et al. Amino acid substitutions at the major insertion loop of *Candida albicans* sterol 14alpha-demethylase are involved in fluconazole resistance. *PLoS One* 2011;6:e21239.
 28. Scorzoni L, de Paula E, Silva AC, Marcos CM, et al. Antifungal therapy: new advances in the understanding and treatment of mycosis. *Front Microbiol* 2017;8:36.
 29. Roberts CW, McLeod R, Rice DW, et al. Fatty acid and sterol metabolism: potential antimicrobial targets in apicomplexan and trypanosomatid parasitic protozoa. *Mol Biochem Parasitol* 2003;126:129–42.
 30. Le Pape P, Zidane M, Abdala H, More MT. A glycoprotein isolated from sponge, *Pachymatisma johnstonii*, has anti-leishmanial activity. *Cell Biol Intern* 2000;24:51–6.
 31. Senda K, Yoshioka H, Doke N, Kawakita K. A cytosolic phospholipase A2 from potato tissues appears to be patatin. *Plant Cell Physiol* 1996;37:347–53.